Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Leonardo Biosystems receives $2.5M grant to accelerate commercialization of new technologies

Arrowhead Research Corporation announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies. Leonardo Biosystems, co-founded by prominent nanoscientist Dr. Mauro Ferrari, professor at the University of Texas, and Arrowhead's, CEO Dr. Christopher Anzalone, is engineering a multi-stage drug delivery platform to improve the effectiveness of drug therapy, particularly for cancer.

7 Jun 2010

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.

7 Jun 2010

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Emisphere Technologies, Inc. today announced that it has entered into an expanded relationship with Novartis Pharma AG pursuant to which Novartis has cancelled the Company's Convertible Promissory Note. The Note was originally issued to Novartis on December 1, 2004 in connection with the Research Collaboration and Option License Agreement between the parties of that date and was originally due December 1, 2009. Previously, Novartis had agreed to extend the maturity date to June 4, 2010.

4 Jun 2010

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Particle Sciences has expanded its Bioanalytic Service's offerings to include Dried Blood Spot LC/MS/MS analysis (DBS). DBS is a growing area of interest because of its advantages in sample collection, stability, and simplified storage requirements. By using DBS, sample collection and processing is greatly simplified resulting in decreased costs, increased safety and greater comfort for test subjects.

4 Jun 2010

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

ULURU Inc. announced today that advanced applications of the Nanoflex technology, related to future products in drug delivery and tissue engineering, will be presented at the 11th annual New Cardiovascular Horizons Meeting to be held in New Orleans, Louisiana on June 2-5, 2010. This meeting is the largest medical meeting that focuses on peripheral artery disease and peripheral interventions, including wound care for vascular ulcers, the application of advanced therapies for limb salvage and amputation prevention.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection.

3 Jun 2010

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Cure Alzheimer's Fund recently awarded the University of Texas Health Science Center at Houston and the University of Houston a $150,000 grant to fund innovative research on Alzheimer's disease, which currently affects 5.3 million Americans and their families and is the most common cause of dementia in the elderly.

3 Jun 2010

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

BD Diagnostics, a segment of BD, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS Assay for Group B Streptococcus on the BD MAX System. The BD MAX System is a next-generation automated workstation for molecular testing designed to streamline workflow and offer full walkaway automation to accommodate varying workloads for maximum lab efficiency and flexibility.

From BD (Becton, Dickinson and Company) 3 Jun 2010

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

US Oncology, Inc., the nation's leading integrated oncology company, today announced its new iKnowMed™ Technology Platform to support community oncologists nationwide. This new platform enhances cancer care quality and practice efficiency through integrated, oncology-specific technologies that enable community oncologists to solve challenges in the areas of care delivery, drug management, and revenue cycle management.

2 Jun 2010

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded two new patents in Japan and Ukraine.

2 Jun 2010

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.

29 May 2010

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor David Zaharoff has been awarded a Transition Career Development Award by the National Cancer Institute to further his research on Interleukin-12, a powerful cytokine that shows great promise for therapeutic treatment of numerous types of cancer.

28 May 2010

Emisphere Technologies announces further extension of Convertible Promissory Note maturity date

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere's Convertible Promissory Note to June 4, 2010.

27 May 2010

Prohibiting cap messages will increase medication errors: Survey

At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.

27 May 2010

Sanofi-aventis, MIT announce strategic alliance agreement for SABIP

Sanofi-aventis announced today a strategic alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program.

27 May 2010

Impax Laboratories, IGI Laboratories announce product development and supply agreement

Impax Laboratories, Inc. today announced that it has entered into a product development and supply agreement with IGI Laboratories, Inc., a formulation and manufacturing company. IGI will be responsible for developing two topical drug products, obtaining FDA marketing approvals, and manufacturing the commercial products.

27 May 2010

Important milestone in development of ORMD-0801 published in DOM journal

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.

26 May 2010

Abstract submissions, registration now open for 2nd International Symposium on MR-guided Focused Ultrasound

Scheduled for October 17-20, 2010 at the Westfields Marriott near Dulles International Airport, Washington, DC, the symposium will be a premier event for scientists, clinicians and others interested in current and future applications of MR-guided focused ultrasound. The program will offer a multifaceted exploration of this emerging field and feature plenary sessions, panel discussions, poster presentations and technical exhibits.

26 May 2010

Drug Delivery News and Research

Further Reading

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Leonardo Biosystems receives $2.5M grant to accelerate commercialization of new technologies

Phase III trial comparing PHP with melphalan to BAC for hepatic metastases highlighted at ASCO 2010

Novartis cancels Emisphere Technologies' Convertible Promissory Note

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Advanced applications of Nanoflex technology to be presented at New Cardiovascular Horizons Meeting

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Nanosponge delivery system more effective at reducing tumor growth than direct injection: Study

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

BD Diagnostics receives 510(k) clearance to market GBS assay on BD MAX System

US Oncology introduces new KnowMed Technology Platform to support oncologists nationwide

Generex awarded new patents in Japan and Ukraine for buccal drug delivery platform technologies

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

Biomedical engineering professor receives Transition Career Development Award

Emisphere Technologies announces further extension of Convertible Promissory Note maturity date

Prohibiting cap messages will increase medication errors: Survey

Sanofi-aventis, MIT announce strategic alliance agreement for SABIP

Impax Laboratories, IGI Laboratories announce product development and supply agreement

Important milestone in development of ORMD-0801 published in DOM journal

Abstract submissions, registration now open for 2nd International Symposium on MR-guided Focused Ultrasound

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News